GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nurix Therapeutics Inc (NAS:NRIX) » Definitions » Asset Turnover

Nurix Therapeutics (Nurix Therapeutics) Asset Turnover : 0.05 (As of Feb. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nurix Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Nurix Therapeutics's Revenue for the three months ended in Feb. 2024 was $16.59 Mil. Nurix Therapeutics's Total Assets for the quarter that ended in Feb. 2024 was $334.14 Mil. Therefore, Nurix Therapeutics's Asset Turnover for the quarter that ended in Feb. 2024 was 0.05.

Asset Turnover is linked to ROE % through Du Pont Formula. Nurix Therapeutics's annualized ROE % for the quarter that ended in Feb. 2024 was -89.95%. It is also linked to ROA % through Du Pont Formula. Nurix Therapeutics's annualized ROA % for the quarter that ended in Feb. 2024 was -49.70%.


Nurix Therapeutics Asset Turnover Historical Data

The historical data trend for Nurix Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nurix Therapeutics Asset Turnover Chart

Nurix Therapeutics Annual Data
Trend Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Asset Turnover
Get a 7-Day Free Trial 0.70 0.08 0.07 0.09 0.20

Nurix Therapeutics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.09 0.06 0.05 0.05

Competitive Comparison of Nurix Therapeutics's Asset Turnover

For the Biotechnology subindustry, Nurix Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nurix Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Nurix Therapeutics's Asset Turnover falls into.



Nurix Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Nurix Therapeutics's Asset Turnover for the fiscal year that ended in Nov. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Nov. 2023 )/( (Total Assets (A: Nov. 2022 )+Total Assets (A: Nov. 2023 ))/ count )
=76.987/( (416.759+355.598)/ 2 )
=76.987/386.1785
=0.20

Nurix Therapeutics's Asset Turnover for the quarter that ended in Feb. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=16.585/( (355.598+312.674)/ 2 )
=16.585/334.136
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Nurix Therapeutics  (NAS:NRIX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Nurix Therapeutics's annulized ROE % for the quarter that ended in Feb. 2024 is

ROE %**(Q: Feb. 2024 )
=Net Income/Total Stockholders Equity
=-166.072/184.6205
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-166.072 / 66.34)*(66.34 / 334.136)*(334.136/ 184.6205)
=Net Margin %*Asset Turnover*Equity Multiplier
=-250.33 %*0.1985*1.8099
=ROA %*Equity Multiplier
=-49.70 %*1.8099
=-89.95 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Nurix Therapeutics's annulized ROA % for the quarter that ended in Feb. 2024 is

ROA %(Q: Feb. 2024 )
=Net Income/Total Assets
=-166.072/334.136
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-166.072 / 66.34)*(66.34 / 334.136)
=Net Margin %*Asset Turnover
=-250.33 %*0.1985
=-49.70 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Nurix Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Nurix Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Nurix Therapeutics (Nurix Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1700 Owens Street, Suite 205, San Francisco, CA, USA, 94158
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Executives
Houte Hans Van officer: Chief Financial Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Christine Ring officer: General Counsel C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Gwenn Hansen officer: Chief Scientific Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Stefani Wolff officer: EVP and COO C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080
Edward C Saltzman director C/O NURIX THERAPEUTICS, 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Paul M Silva director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Judith A Reinsdorf director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Pierre Beaurang officer: Chief Business Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Clay B Siegall director 21823 30TH DR SE, BOTHELL WA 98021
Ponoi Capital, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Ii Management, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital Ii, Lp 10 percent owner 1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129

Nurix Therapeutics (Nurix Therapeutics) Headlines

From GuruFocus

Nurix Therapeutics to Participate in Upcoming Investor Conferences

By Value_Insider Value_Insider 11-02-2022